Triple-drug antiretroviral regimens that are widely used in the United States and Europe against one HIV-1 subtype appear to be effective in South African patients infected with a different HIV-1 subtype who also have tuberculosis (TB) or Kaposi's sarcoma (KS), according to a study published in the Feb.1 issue of The Journal of Infectious Diseases, now available online. The South African subtype, known as subtype C, is rapidly spreading in developing countries, where TB and KS are major factors in AIDS morbidity and mortality. Since the triple-drug regimens have markedly reduced the morbidity and mortality associated with the subtype that predominates in developed countries (subtype B), the implication is that they may be similarly effective against the C subtype in developing countries as well.
The authors, Edana Cassol and coworkers in Durban, South Africa and the United States, studied 49 patients with previously untreated HIV-1 infection, 21 of whom had pulmonary TB and 28 of whom had KS. Patients in the TB group first received standard TB treatment, then an antiretroviral combination that has been successfully used to treat HIV-1 subtype B infections in patients with active TB--didanosine, lamivudine, and efavirenz, all purchased from Western manufacturers. KS patients received a combination of generic stavudine, lamivudine, and nevirapine, all manufactured in India; some also received cancer chemotherapy. Responses to antiretroviral therapy were measured in part by plasma HIV RNA levels and the number of peripheral blood CD4 cells, which help to orchestrate immune responses.
After three months, 94 percent of the TB group and 80 percent of the Kaposi group had undetectable HIV RNA levels--rates equivalent to or better than those in studies involving Western patients infected with the B subtype. The decrease occurred rapidly during the first 7 days of treatment, then gradually until virus was undetectable--a pattern reported in Western B subtype-Page: 1 2 Related medicine news :1
Contact: Steve Baragona
Infectious Diseases Society of America
. Study shows patch therapy may be as effective as oral medications2
. Novel therapy tested in mice could chase away cat allergies3
. Drug therapy may be comparable to invasive cardiac procedures for elderly patients with heart attack4
. Risk of cardiac death after radiotherapy for breast cancer has declined, study finds5
. Antiretroviral therapy may prevent excess risk of some cancers in people with HIV6
. Bevacizumab combined with chemotherapy prolongs survival for some patients with advanced lung cancer7
. Breakthrough in medical research: New chemotherapy gives hope to brain tumour patients8
. Two years after gene therapy treatments, severe angina patients showed prolonged clinical benefit9
. Combining PET and CT scans leads to more accurate radiation therapy for lung cancer patients10
. Cognitive behavioral therapy and medication is effective in the treatment of panic disorder11
. Study finds drug eluting stents as effective as vascular brachytherapy in preventing restenosis